COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetic Study of CXB909 in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01505907
Recruitment Status : Unknown
Verified January 2012 by CeNeRx BioPharma Inc..
Recruitment status was:  Not yet recruiting
First Posted : January 9, 2012
Last Update Posted : January 9, 2012
Information provided by (Responsible Party):
CeNeRx BioPharma Inc.

Brief Summary:
The primary objective of this dose escalation study is to examine the safety, tolerability, and pharmacokinetic properties of single-doses of CXB909, compared to placebo, in healthy male volunteers. This study may evaluate five (5) dose levels of CXB909; however, the number of dose levels, as well as the dosages, may be adjusted after evaluation of in-study analysis of the safety, tolerability, and pharmacokinetic data. This study will attempt to identify the maximum tolerated single dose of CXB909.

Condition or disease Intervention/treatment Phase
Healthy Drug: CXB909 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Official Title: Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers
Study Start Date : December 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2014

Arm Intervention/treatment
Experimental: CXB909 15mg
CXB909 15mg
Drug: CXB909

Experimental: CXB909 30mg Drug: CXB909

Experimental: CXB909 60mg Drug: CXB909

Experimental: CXB909 120mg
Drug: CXB909

Experimental: CXB909 250mg Drug: CXB909

Primary Outcome Measures :
  1. Pharmacokinetic Parameters [ Time Frame: 1 Week ]
    The PK parameters to be determined will include: Tmax, t1/2, Cmax, AUClast, AUCinf, Vd/F and CL/F.

Secondary Outcome Measures :
  1. Safety [ Time Frame: 1 Week ]
    Descriptive statistics will be reported for adverse events; systolic and diastolic blood pressures; pulse; the respiration rate; QTC, PR, and QRS intervals; and the laboratory parameters. QTC will be calculated using both the Bazett and Fridericia corrections.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male, 18 to 50 years of age.
  2. Able to read, understand, and provide written/dated informed consent before screening in the study, and must be willing to comply with all study procedures.
  3. In good general health as ascertained by thorough medical history, physical examination (PE)including measurement of supine and standing vital signs, clinical laboratory studies, and 12-lead electrocardiogram (EKG).
  4. Body Mass Index (BMI) > 21 and < 30.
  5. Willing and able to be confined to the clinical research unit as required by the protocol.

Exclusion Criteria:

  1. Presence of a significant acute or chronic medical disorder that might complicate evaluation of the study drug such as:

    • Any cardiovascular or cardiac condition.
    • Supine SBP≥145 mmHg and/or DBP ≥90 mmHg at Screening.
    • Diabetes mellitus.
    • Malignancy and/or chemotherapy within two years of screening, other than basal cell carcinoma. Malignancies more than two years prior may not preclude participation; however, must be reviewed on a case-by-case basis by the CeNeRx BioPharma, Inc., medical monitor.
    • Known or suspected hypersensitivity to CXB909.
    • Any gastrointestinal disease or digestive disorder, neurological, pulmonary, hepatic, renal, hematologic, endocrine and/or metabolic disease or disorder.
  2. Current or past psychiatric illness.
  3. Use of any prescription medications within 14 days of study drug administration.
  4. Use of any over-the-counter (OTC) medication within seven days of study drug administration (including herbal remedies).
  5. History of substance abuse, including alcohol abuse as defined by DSM-IV criteria,within the past 12 months.
  6. Current use of tobacco products or any nicotine-containing products (e.g., gum, patch)for the prior three months.
  7. Consumption of alcohol or caffeine/xanthine-containing drinks or foods within 72 hours of dosing on Day 1 (including any type of wines, caffeinated or decaffeinated herbal tea, and grapefruit products (e.g., fresh, canned, or frozen), Seville oranges and pomelos).
  8. Abnormal screening medical/physical examination, unless the abnormality is considered unlikely to be affected by study participation, or confound interpretation of safety data.
  9. A clinically significant clinical laboratory or EKG abnormality at screening; includes any of the following: aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphate (ALP) >2.0 x the upper limit of normal (ULN); total bilirubin >1.5 x the ULN;serum creatinine >1.5 x the ULN; blood urea nitrogen (BUN) >1.5 x the ULN; and thyroid stimulating hormone (TSH) and/or free thyroxine (T4) outside of the normal limits.
  10. Test positive for: Urine cannabinoids, cocaine, amphetamines, barbiturates, opiates or benzodiazepines, serum alcohol, hepatitis B or C, or nicotine use.
  11. HIV/AIDS.
  12. Participation in a clinical investigation within the last 45 days of screening.
  13. Any other condition which, in the investigator's opinion, may place the subject at greater than normal risk of developing complications.
  14. Donation of any blood product (one pint or greater) within the previous eight weeks of screening.
  15. Planning to donate any blood product within eight weeks of end of study.
Layout table for additonal information
Responsible Party: CeNeRx BioPharma Inc. Identifier: NCT01505907    
Other Study ID Numbers: CXB909-100
First Posted: January 9, 2012    Key Record Dates
Last Update Posted: January 9, 2012
Last Verified: January 2012
Keywords provided by CeNeRx BioPharma Inc.:
Healthy Males